BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 5014777)

  • 1. Antigenicity of L1210 leukemic sublines induced by drugs.
    Nicolin A; Vadlamudi S; Goldin A
    Cancer Res; 1972 Apr; 32(4):653-7. PubMed ID: 5014777
    [No Abstract]   [Full Text] [Related]  

  • 2. Differences in the immunogenicity of leukemia L1210 sublines in DBA-2 mice.
    Mihich E; Kitano M
    Cancer Res; 1971 Dec; 31(12):1999-2003. PubMed ID: 5120297
    [No Abstract]   [Full Text] [Related]  

  • 3. Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay.
    Fuji H; Mihich E
    Cancer Res; 1975 Apr; 35(4):946-52. PubMed ID: 1090366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic differences between leukemia L1210 and a subline resistant to methylglyoxal-bis(guanylhydrazone).
    Kitano M; Mihich E; Pressman D
    Cancer Res; 1972 Feb; 32(2):181-6. PubMed ID: 5061638
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
    Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
    Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of murine leukemia antigen on L1210 parental and drug-resistant sublines.
    Strzadala L; Opolski A; Radzikowski C; Mihich E
    Cancer Res; 1981 Dec; 41(12 Pt 1):4934-7. PubMed ID: 7306993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of tests of chemotherapeutic agents involving repeated drug treatment.
    Ullman NS; Jacquez JA
    Biometrics; 1973 Dec; 29(4):677-93. PubMed ID: 4785233
    [No Abstract]   [Full Text] [Related]  

  • 8. Serological analysis of H-2 antigens expression on the cell surface of drug- and lectin-resistant mouse tumor cells.
    Opolski A; Duś D; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1986; 34(1):21-34. PubMed ID: 3778114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collateral sensitivity of resistant lines of mouse leukemias L1210 and L5178Y.
    Schmid FA; Hutchison DJ
    Cancer Res; 1972 Apr; 32(4):808-12. PubMed ID: 5014791
    [No Abstract]   [Full Text] [Related]  

  • 10. Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. III. Control of host resistance to drug-resistant L1210 sublines by H-2-linked and non-H-2-linked genes.
    Fuji H; Murakami M
    J Natl Cancer Inst; 1983 Jan; 70(1):119-25. PubMed ID: 6296515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide.
    Bonmassar E; Bonmassar A; Vadlamudi S; Goldin A
    Cancer Res; 1972 Jul; 32(7):1446-50. PubMed ID: 4402275
    [No Abstract]   [Full Text] [Related]  

  • 12. Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents.
    Kataoka T; Kobayashi H; Sakurai Y
    Cancer Res; 1978 May; 38(5):1202-7. PubMed ID: 639053
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunologic cross-reactivity of antigen(s) induced by drug treatment in two leukemic sublines.
    Nicolin A; Bini A; Di Padova F; Goldin A
    J Immunol; 1976 May; 116(5):1347-9. PubMed ID: 58028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytogenetic characteristics of the leukemia L1210 strain in the development of drug resistance].
    Goncharova SA; Minenkova EA; Fomina MM; Demidova NS
    Eksp Onkol; 1984; 6(4):38-41. PubMed ID: 6499750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
    Kim K; Blechman WJ; Riddle VG; Pardee AB
    Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
    Fuji H
    Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L; Fuji H
    Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.
    Contessa AR; Bonmassar A; Giampietri A; Circolo A; Goldin A; Fioretti MC
    Cancer Res; 1981 Jun; 41(6):2476-82. PubMed ID: 7016315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods.
    Fuji H; Mihich E; Pressman D
    J Natl Cancer Inst; 1979 Jun; 62(6):1503-10. PubMed ID: 286122
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug resistance induction and cross-resistance studies with Pt-complexes.
    Hrubisko M; Balázová E; Ujházy V
    Neoplasma; 1984; 31(6):649-53. PubMed ID: 6542968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.